IKS014 in Advanced Solid Tumors That Express HER2
Recruiting now · Phase 1
Conditions studied: Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
In brief
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Key facts
- Study ID
- NCT05872295
- Run by
- Iksuda Therapeutics Ltd.
- People needed
- 165
- Starts
- 2023-09-14
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-05-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
- START Dallas - Fort Worth — Fort Worth, Texas, United States (enrolling)
- Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit — Concord, New South Wales, Australia (enrolling)
- Macquarie University — Sydney, New South Wales, Australia (enrolling)
- Westmead Hospital — Westmead, New South Wales, Australia (enrolling)
- Peninsula & South Eastern Haematology and Oncology Group (PSEHOG) — Frankston, Victoria, Australia (enrolling)
- Alfred Health — Melbourne, Victoria, Australia (enrolling)
- Linear Clinical Research — Nedlands, Western Australia, Australia (enrolling)
- Auckland City Hospital — Auckland, New Zealand (enrolling)
- National Cancer Centre Singapore — Singapore, Singapore (enrolling)
- Tan Tock Seng Hospital — Singapore, Singapore (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.